Abstract
Aim:
To study the efficacy of antiviral treatment with PNA for the duck model of HBV (DHBV)-infected ducks. PNA is a 2-amine-9-(2,3-dideoxy-2,3-dihydro-β-D-arabinofuranosyl)-6-methoxy-9H-purine.
Methods:
The Sichuan Mallard ducklings in the hepatitis B virus model were treated with PNA, a new antiviral agent. DHBV DNA from the blood serum and liver tissues were measured at 0, 5, and 10 d during the treatment and at 3 d withdrawal by real-time PCR. The duck hepatitis B surface antigen (DHBsAg) in the liver cells was observed by Immunohistochemistry (IHC). Pathological changes in the liver tissues were also observed. Control group I was administered with distilled water and control group II was administered with 3-thiacytidine. Treatment group I was administered with PNA at a dose of 40 mg/kg and treatment group II was administered perorally (po) with PNA at a dose of 80 mg/kg. Treatment group III was administered with PNA at a dose of 20 mg/kg and treatment group IV was intravenously administered with PNA at a dose of 40 mg/kg. Each group contained 15 ducklings.
Results:
PNA can significantly lower the DHBV replication levels in serum and liver. Compared with control group II, there were no significant differences in inhibiting efficacy in treatment groups I and III (P>0.05) and there were significant differences in inhibiting efficacy in treatment groups II and IV (P<0.05). Interestingly, significant differences were observed at 3 d withdrawal. The DHBV replication levels in each group slightly increased at 3 d withdrawal, but rebounded slightly in the PNA treatment groups than in control group II (P<0.05). The DHBV replication levels in the treatment groups were lower than in control group I. The DHBV replication levels in sera had a positive relationship with that in the liver, but the DHBV replication levels in the liver was lower than that in sera. Pathological changes in the treatment groups were obviously improved and the changes were associated with liver viral DNA levels.
Conclusion:
The results demonstrate that PNA is a strong inhibitor of DHBV replication in the DHBV-infected duck model.
Similar content being viewed by others
Article PDF
References
Kane MA . Global status of hepatitis B immunisation. Lancet 1996; 348: 696.
Blumberg BS . Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. PNAS 1997; 94: 7121–5.
Lee WM . Hepatitis B virus infection. N Engl J Med 1997; 337: 1733–45.
Lin KW, Kirchner JT . Hepatitis B. Am Fam Physician 2004; 69: 75–82.
Mason WS, Halpern MS, England JM, Seal G, Egan J, Coates L, et al. Experimental transmission of duck hepatitis B virus. Virology 1983; 131: 375–84.
Mason WS, Seal G, Summers J . Virus of Peking ducks with structural and biological relatedness to human hepatitis B virus. J Virol 1980; 36: 829–36.
Ling Z . Research of JMS inhibitory effect on Duck HBV in vivo. Acta Pharmacol Sin 2003; 24: 379–80.
Seigneres B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, et al. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2003; 47: 1842–52.
Luca GG, Amber M, Heike M, Rick K, Robert H, Silverman BR, et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002; 76: 2617–21.
Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ . Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 2002; 46: 82–8.
Foster WK, Miller DS, Marion PL, Colonno RJ, Kotlarski I, Jilbert AR . Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003; 47: 2624–35.
Foster WK, Miller DS, Scougall CA, Kotlarski I, Colonno RJ, Jilbert AR . Effect of antiviral treatment with entecavir on age-and dose-related outcomes of duck hepatitis B virus infection. J Virol 2005; 79: 5819–32.
Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, et al. Quantitation of hepatitis B virus genomic DNA by real-rime detection PCR. J Clin Microbiol 1999; 37: 2899–903.
Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS . Real-time PCR quantitation of hepatitis B virus DNA using automated sample preparation and murine cytomegalovirus internal control. J Virol Methods 2005; 126: 207–13.
Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Valdes A, et al. Quantitative detection of hepatitis B virus DNA in sera by a new rapid real-time fluorescence PCR assay. J Viral Hepatitis 2001; 8: 465–71.
Zanella AR, Domenighini D, Albertini A, Cariani E . Quantitative analysis of hepatitis B virus DNA by real-time amplification. Eur J Clin Microbiol Infect Dis 2002; 21: 22–6.
Cullen JM, Marion PL, Newbold JE . A sequential histologic and immunohistochemical study of duck hepatitis B virus infection in Pekin ducks. Vet Pathol 1989; 26: 164–72.
Jilbert AR, Botten JA, Miller DS, Bertram EM, Hall PDLM, Kotlarski I, et al. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection. Virology 1998; 243: 273–82.
George GC, Paul BS, Ernest CW, Chak HX, Lee KM, Lau WY . Immunohistochemical analysis of pro-apoptotic Bid level in chronic hepatitis, hepatocellular carcinoma and liver metastases. Cancer letters 2001; 172: 75–82.
Kangmin Z, Robert SL, Edward AB, Marianna KB . The relationship of hepatitis history and pathological diagnosis of primary liver cancer. J Clinical Epidemiol 1997; 50: 297–301.
Ku T, Ha W, Zhang LZ, Ha R, Ha Y, Cheng Q, et al. Epidemio-logical survey of HBsAg carriers in the Uighur and Han populations in the Khotan area of Xinjiang autonomous region. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 1287–8.
Beck IA, Drennan KD, Melvin AJ, Mohan KM, Herz AM, Alarcon J, et al. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the field. J Clin Microbiol 2001; 39: 29–33.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by grants from National Key Technologies Research and Development Program of China (No 2004BA901A03) and Program for Changjiang Scholars and Innovative Research Team in University (No IRTO753).
Rights and permissions
About this article
Cite this article
Chen, Zy., Cheng, Ac., Wang, Ms. et al. Antiviral effects of PNA in duck hepatitis B virus infection model. Acta Pharmacol Sin 28, 1652–1658 (2007). https://doi.org/10.1111/j.1745-7254.2007.00641.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00641.x
Keywords
This article is cited by
-
Establishment of a hydrodynamic delivery system in ducks
Transgenic Research (2024)
-
Walking through the wonder years of artificial DNA: peptide nucleic acid
Molecular Biology Reports (2020)
-
In Vitro Anti-hepatitis B Virus Activity of 2′,3′-Dideoxyguanosine
Virologica Sinica (2018)
-
Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®
Chinese Medicine (2017)
-
Reproductive toxicity study with a novel deoxyguanosine analogue (Metacavir) in pregnant SD rats
Frontiers of Medicine (2015)